基于关联规则分析肿瘤患者帕博利珠单抗联合用药特征  

Characteristics of drug combination for Pembrolizumab in cancer patients based on association rules

作　　者：孙晓利[1] 白万军[2] 冯晓杰[1] 刘红[1] 高书萍[1] 杜文力[1] 冯锐[1] SUN Xiaoli;BAI Wanjun;FENG Xiaojie(Department of Pharmacy,The Fourth Hospital of Hebei Medical University,Hebei,Shijiazhuang 050011,China;不详)

机构地区：[1]河北医科大学第四医院药学部,石家庄市050011 [2]河北省人民医院药学部

出　　处：《河北医药》2023年第2期297-301,共5页Hebei Medical Journal

基　　金：河北省医学科学研究重点课题计划项目(编号:20221338);河北省药学会医院药学科研项目面上课题(编号:2020-Hbsyxhms0028)。

摘　　要：目的 探究免疫检查点抑制剂帕博利珠单抗的临床应用现状及利用SPSS Clementine关联规则分析药物联用特征。方法 统计患者的基本信息、医嘱信息、用药顺序、不良反应及药物联用,并对以上数据利用Apriori算法及关联规则进行关联性分析,探究联合用药的规律。结果 本次共统计使用帕博利珠单抗179例患者,共计410例次。男性患者占多数(134例,74.86%),年龄60~69岁患者居多(80例,44.69%),患癌类型主要为肺癌(81例,45.25%)、食管癌(29例,16.20%)、胃癌(11例,6.25%)。帕博利珠单抗联合化疗共179例次,占43.66%。采用Clementine 12.0软件建立关联规则,帕博利珠单抗联合化疗方案最常用的是紫杉醇+铂类药物。结论 利用数据挖掘关联规则分析帕博利珠单抗联合用药规律,为临床合理用药提供参考。Objective To explore current situation of clinical application of Pembrolizumab,an immune checkpoint inhibitor,and to analyze characteristics of drug combination by SPSS Clementine association rules.Methods Basic information,medical advice,medication order,adverse reactions and drug combination of patients were collected and subject to correlation analysis by using Apriori algorithm and association rules,and laws for drug combination were explored.Results A total of 179 patients receiving Pembrolizumab were recorded,and a total of 410 case times were hit.The majority of patients were male(134 cases,74.86%) and aged ranging from 6o to 69 years old(80 cases,44.69%),main types of cancer were lung cancer(81 cases,45.25%),esophageal cancer(29 cases,16.20%) and gastric cancer(11 cases,6.25%).A total of 179 case times were treated with Pembrolizumab combined with chemotherapy,accounting for 43.66%.Association rules were set up by applying Clementine 12.0 software,and the regimen of Paclitaxel+ platinum drugs was the most commonly combination chemotherapy regimen for Pembrolizumab.Conclusion The drug combination rules for Pembrolizumab is analyzed by data mining,and reference for clinical rational medications is provided.

关 键 词：帕博利珠单抗 关联规则 不良反应 联合用药 

分 类 号：R965.3[医药卫生—药理学]